Eplerenone: all 95 studies that test it

Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Reducing Arterial Inflammation Using Eplerenone and Statins in HIVNot yet recruitingNCT07892664Phase 2/3
• Cardiac Improvement by Eplerenone Among Patients Under Cyclosporine or Tacrolimus for Kidney Transplantation.Not yet recruitingNCT07828223Phase 3
• Eplerenone and IOP in Healthy AdultsNot yet recruitingNCT07795762Phase 1
• Early Aldo Blockade in Subclinical PANot yet recruitingNCT07727252Phase 2/3
• Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic StenosisNot yet recruitingNCT07539259Phase 2
• Cardiac Effects of Mineralocorticoid Receptor Antagonism After Hypertensive Disorders of PregnancyRecruitingNCT07238400Phase 2
• Swedish Cardiac And Renal Failure Study-1RecruitingNCT07029503Phase 2
• Vascular Effects of High-Salt After PreeclampsiaRecruitingNCT06749418Early Phase 1
• Optimal Medical Treatment of Difficult-to-treat HypertensionRecruitingNCT06275763Phase 4
• The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.RecruitingNCT06208072Not applicable
• Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart DiseaseNot yet recruitingNCT06168994Phase 4
• Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical TreatmentRecruitingNCT05797558Not applicable
• Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in HypertensionRecruitingNCT05593055Phase 4
• Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.RecruitingNCT05198791Phase 2
• Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical StudyRecruitingNCT05030545Phase 4
• The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.RecruitingNCT04450953Phase 3
• A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart FailureEnrolling by invitationNCT03984591Phase 4
• Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in ObesityCompletedNCT04519164Phase 4Results posted
• Pressure Assessment to Improve Outcomes After TAVR: a RegistryCompletedNCT03923530Early Phase 1Results posted
• Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)CompletedNCT02740179Not applicableResults posted
• Cardiometabolic Effects of Eplerenone in HIV InfectionTerminatedNCT02629094Phase 2Results posted
• Evaluating Alternative Medical Therapies in Primary HyperparathyroidismCompletedNCT02525796Phase 2/3Results posted
• Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyCompletedNCT02354352Phase 3Results posted
• Endogenous Renin-Angiotensin-Aldosterone System and Glucose MetabolismCompletedNCT02034435Phase 4Results posted
• The Role of Aldosterone on Augmented Exercise Pressor Reflex in HypertensionCompletedNCT01996449Phase 2Results posted
• Eplerenone for the Treatment of Central Serous ChorioretinopathyCompletedNCT01990677Not applicableResults posted
• The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart DiseaseTerminatedNCT01971593Phase 4Results posted
• Eplerenone for Central Serous ChorioretinopathyCompletedNCT01822561Phase 2Results posted
• Effect of Eplerenone on Postprandial Inflammatory Response in Healthy AdultsCompletedNCT01786551Not applicableResults posted
• Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular DystrophyCompletedNCT01521546Not applicableResults posted
• Hypoglycemia and the Mineralocorticoid ReceptorCompletedNCT01394627Not applicableResults posted
• Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial InfarctionCompletedNCT01176968Phase 4Results posted
• Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart FailureCompletedNCT01115855Phase 3Results posted
• Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in ObesityTerminatedNCT00608465Phase 4Results posted
• Diurnal Variation of Plasminogen Activator Inhibitor-1CompletedNCT00515021Phase 4Results posted
• Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs AloneCompletedNCT00391846Phase 4Results posted
• A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure MedicinesCompletedNCT00232180Phase 3Results posted
• EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial IschemiaCompletedNCT00187889Phase 4Results posted
• MR and Inflammation After PreeclampsiaActive, not recruitingNCT07345845Early Phase 1
• MR Antagonist and LSD1CompletedNCT04840342Phase 4
• Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)WithdrawnNCT04746495Phase 4
• Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)TerminatedNCT04300881Phase 2
• Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive PatientsCompletedNCT03476616Phase 4
• Eplerenone as a Supplement to Epidural Steroid InjectionsWithdrawnNCT03418649Phase 4
• Reduction of Left Ventricular Hypertrophy After Eplerenone TherapyCompletedNCT03186742Phase 4
• This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are ToleratedCompletedNCT03165240Phase 1
• Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous ChorioretinopathyStatus unknownNCT03079141Phase 4
• The Role of Aldosterone in Circulatory Disorders Within Type 2 DiabetesCompletedNCT03017703Not applicable
• Pharmacokinetics Study of Eplerenone Coated TabletsWithdrawnNCT02957435Phase 1
• The Role of Minerelocorticoid Receptor on Modulating Aldosterone ProductionCompletedNCT02871648Phase 1
• Mineralocorticoid Receptor Antagonists in Type 2 DiabetesCompletedNCT02809963Phase 4
• Pharmacokinetics of Eplerenone TabletWithdrawnNCT02607657Phase 1
• Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)Active, not recruitingNCT02490904Phase 3
• Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian PopulationCompletedNCT02462499Phase 4
• Eplerenone in the Management of Abdominal Aortic AneurysmsStatus unknownNCT02345590Phase 4
• A Study of the Beneficial Effects of Eplerenone on Central Serous ChorioretinopathyStatus unknownNCT02215330Phase 2/3
• Eplerenone For the Treatment of Chronic Central Serous ChorioretinopathyStatus unknownNCT02153125Phase 2
• The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDiumCompletedNCT02118753Not applicable
• Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular HypertrophyStatus unknownNCT01893788Phase 4
• Aldosterone Antagonism and Microvascular FunctionTerminatedNCT01887119Phase 4
• PHOspholamban RElated CArdiomyopathy STudy - InterventionCompletedNCT01857856Phase 3
• Eplerenone and Extracellular Adenosine FormationCompletedNCT01837108Phase 4
• EPLErenone in CsA-Treated Recipients (EpleCsAT): SafetyStatus unknownNCT01834768Phase 2
• The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)Status unknownNCT01832558Not applicable
• Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side EffectsWithdrawnNCT01801228Phase 2
• Detection of Diffuse Scar in Patients With DiabetesWithdrawnNCT01794091Phase 4
• Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast CancerTerminatedNCT01708798Phase 2/3
• Eplerenone in Hemodialysis TrialCompletedNCT01650012Not applicable
• Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 DiabetesCompletedNCT01586442Phase 3
• The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on ProteinuriaCompletedNCT01541267Phase 4
• Effect of Eplerenone on Endothelial Function in Metabolic SyndromeCompletedNCT01319344Phase 3
• Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) PatientsWithdrawnNCT01302236Phase 4
• CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy RegressionWithdrawnNCT01275352Phase 4
• Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney FunctionTerminatedNCT01100203Phase 3
• Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential HypertensionTerminatedNCT00980031Not applicable
• Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fed ConditionsCompletedNCT00865618Phase 1
• Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting ConditionsCompletedNCT00865176Phase 1
• A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese HypertensivesTerminatedNCT00825188Not applicable
• Eplerenone in Systemic Right VentricleCompletedNCT00703352Phase 4
• A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate HypertensionTerminatedNCT00649311Phase 2
• EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After CardioversionTerminatedNCT00647192Phase 2
• Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?Status unknownNCT00553722Phase 4
• The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart FailureCompletedNCT00505336Not applicable
• Inhibition of Aldosterone in Patients With Chronic Renal DiseaseCompletedNCT00430924Phase 4
• CMR to Assess Fibrosis in Cardiomyopathy Using EplerenoneCompletedNCT00401856Phase 4
• Eplerenone, ACE Inhibition and AlbuminuriaCompletedNCT00315016Phase 2
• Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart FailureTerminatedNCT00293150Phase 4
• Treatment of Supine Hypertension in Autonomic FailureCompletedNCT00223717Phase 1
• Aldosterone and Vascular Disease in Diabetes MellitusCompletedNCT00214825Not applicable
• The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 YearsCompletedNCT00147615Phase 3
• A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.CompletedNCT00147589Phase 3
• Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HTCompletedNCT00147563Phase 4
• Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial HypertensionCompletedNCT00138944Phase 3
• Effects of Eplerenone on Left Ventricular Remodelling Following Heart AttackCompletedNCT00132093Phase 4
• The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart FailureCompletedNCT00082589Phase 4

← Eplerenone overview